COMPANY

Constantiam Biosciences

Keywords: rare disease rare diseases precision medicine

Location: Katy, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.25M (SBIR Phase II 2R44AG084431-02, competing renewal, notice Sep 17, 2026). NIH RePORTER 2R44AG084431-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 2R44AG084431-02
  Organization: CONSTANTIAM BIOSCIENCES INC.; City/State: KATY, TX; Project number: 2R44AG084431-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1252240; Administering IC: National Institute on Aging; Project title: Leveraging high-throughput functional data for assessment of Alzheimer's risk; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 17, 2026 Grant Government grant — SBIR: $1.25M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Jul 28, 2025 Grant Government grant — SBIR: $1.03M (annual award, as published), announced Jul 28, 2025. Agency: NIH/NHGRI. Source: government award database. source ↗

Last 2 years.

Sep 17, 2026 Government grant — SBIR: $1.25M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Jul 28, 2025 Government grant — SBIR: $1.03M (annual award, as published), announced Jul 28, 2025. Agency: NIH/NHGRI. Source: government award database. source ↗